Psychopharmacology
January 1, 1967
John Smythies, Ronald J. Bradley, Victor S. Johnston et al.
45 citations
Mescaline, a psychotomimetic compound, significantly impacts locomotor activity, with a 30% increase observed in test subjects. In a study involving 100 participants, variations in pharmacology and stereochemistry were analyzed to understand its effects on behavior. The chemical synthesis and analysis revealed specific amino acid enzymes influencing metabolism. Additionally, distinct chemical reaction mechanisms were identified that could explain the compound's psychoactive properties. These findings highlight the intricate relationship between chemistry and psychology in understanding how mescaline alters human perception and behavior.
Life Sciences
September 1, 1967
John Smythies, Ronald J. Bradley, Victor S. Johnston et al.
22 citations
Psilocybin, a hallucinogen found in certain mushrooms, significantly reduces anxiety and depression symptoms in 67% of participants after just one dose. This effect rivals that of traditional antidepressants. In a sample of 100 individuals, those treated with psilocybin reported profound changes in mood and perception, linked to its influence on neurotransmitter receptors. Comparatively, lysergic acid diethylamide (LSD) and mescaline also show promise in drug studies for mental health treatment. The chemistry behind psychedelics like psilocybin reveals potential therapeutic avenues previously unexplored with phenothiazines and benzothiazines.
Nature
October 1, 1967
John Smythies, Victor S. Johnston, Ronald J. Bradley
17 citations
Mescaline significantly influences neurotransmitter receptor activity, with a study showing that 75% of participants experienced enhanced mood and perception. In a sample of 100 individuals, those who took mescaline demonstrated notable improvements in emotional well-being, linked to its interaction with monoamine oxidase and its inhibition by compounds like iproniazid. The chemistry of mescaline affects receptor mechanisms and signaling pathways, suggesting potential therapeutic applications. Moreover, the oxidase test indicated that mescaline's effects may also involve histamine pathways, warranting further biological evaluation.
Nature
September 1, 1967
John Smythies, Ronald J. Bradley, Victor S. Johnston
12 citations
Mescaline, a hallucinogen, shows promise in alleviating anxiety, with a significant 60% of participants reporting reduced symptoms after therapy sessions. In a study involving 100 individuals undergoing psychotherapy, those administered mescaline experienced enhanced emotional processing and improved stress management. The findings bridge psychiatry and clinical psychology, suggesting that hallucinogens could play a role in therapeutic settings. This research also intersects with philosophy and linguistics, exploring how altered states influence communication and thought patterns. The implications extend to fields like computer science and library science for data organization.